Schultz to head CDRH for rest of 2004?
This article was originally published in The Gray Sheet
Executive Summary
Device center medical deputy post unlikely to be filled until CDRH obtains a permanent director, according to FDA staff. The agency had previously suggested that a medical deputy appointment was imminent, and that more than 20 candidates were under review (1"The Gray Sheet" April 19, 2004, p. 3). With the April 30 departure of former CDRH director David Feigal, however, staffers say Dan Schultz could remain acting director through the November elections...
You may also be interested in...
CDRH Leadership Changes May Be Imminent; NCI’s Ellen Feigal To Leave Institute
FDA is vetting a list of more than 20 candidates for a CDRH clinical deputy spot - a position that may grow in stature with the potential departure of Director David Feigal
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.